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CD63 Tetraspanin Is a Negative Driver of
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Melanoma Cells
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Carmelo Urso4, Lorenzo Borgognoni5, Sergio Capaccioli1, Lido Calorini1 and Matteo Lulli1
The CD63 tetraspanin is highly expressed in the early stages of melanoma and decreases in advanced lesions, sug-
gesting it as a possible suppressor of tumor progression. We employed loss- and gain-of-gene-function approaches
to investigate the role of CD63 in melanoma progression and acquisition of the epithelial-to-mesenchymal
transition (EMT) program. We used two human melanoma cell lines derived from primary tumors and one primary
human melanoma cell line isolated from a cutaneous metastasis, differing by levels of CD63 expression. CD63-
silenced melanoma cells showed enhanced motility and invasiveness with downregulation of E-cadherin and
upregulation of N-cadherin and Snail. In parallel experiments, transient and stable ectopic expression of CD63
resulted in a robust reduction of cell motility, invasiveness, and protease activities, which was proportional to the
increase in CD63 protein level. Transfected cells overexpressing the highest level of CD63 when transplanted into
immunodeficient mice showed a reduced incidence and rate of tumor growth. Moreover, these cells showed a
reduction of N-cadherin, Vimentin, Zeb1, and a-SMA, and a significant resistance to undergo an EMT program both
in basal condition and in the following stimulation with TGFb. Thus, our results establish a previously unreported
mechanistic link between the tetraspanin CD63 and EMT abrogation in melanoma.
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INTRODUCTION
Melanoma is one of the most aggressive tumors with high
metastatic potential and rate of mortality. The early diagnosis
of localized and thin lesions, Breslow’s depth o1 mm, gives
patients a better chance to survive, whereas for patients with
advanced lesions, Breslow’s depth 41 mm, the outcome is
poor. The depth of melanoma invasion and tumor thickness
are used as predictors of clinical prognosis; however, the
mechanisms underlying melanoma invasion from the epidermis
into the dermis remain poorly characterized. Comparison of
the gene expression profile in primary melanoma without
metastatic disease with melanoma that had developed meta-
static disease demonstrated that key steps in melanoma
progression are represented by the changes associated with
epithelial-to-mesenchymal transition (EMT) (Alonso et al.,
2007). The EMT program involves a transitory change in
epithelial cells that acquire a mesenchymal phenotype charac-
terized by invasive properties, stemness, and metastatic
dissemination (Grunert et al., 2003). Tumor cells undergoing
EMT show reduced expression of E-cadherin, upregulation of
the Snail transcription factor (Cano et al., 2000), and increased
level of N-cadherin (Alonso et al., 2007). Indeed, melanoma
cells transfected with N-cadherin acquire a fibroblast-like
shape, and adenoviral re-expression of E-cadherin down-
regulates N-cadherin and reduces malignancy (Krengel
et al., 2006). Cytokines and hypoxia stimulate the EMT
program in tumor cells (Reichmann et al., 1992; Tepass
et al., 2000; Gottardi et al., 2001), and TGF-b is the most
important inducer of EMT (Oft et al., 1998; Miyazono et al.,
2000; Bhowmick et al., 2001; Bierie and Moses, 2006).
A particular relevance in melanoma progression is played
by CD63 tetraspanin, known as melanoma-associated antigen
ME491 or melanoma-associated antigen MLA1 (Pols and
Klumperman, 2009). Tetraspanins are transmembrane proteins
defined by small and large outer loops, short N-terminal and
C-terminal tails with four transmembrane domains (Maecker
et al., 1997; Hemler, 2003; Wright et al., 2004; Hemler, 2005;
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Ya´n˜ez-Mo´ et al., 2009; Zoller, 2009). They form complexes
termed as tetraspanin-enriched microdomains by interacting
with other tetraspanins and a variety of transmembrane and
cytosolic proteins that are required for their function.
CD63 expression is strong in the early stages of melanoma
and is weak or absent in the later stages (Atkinson et al., 1984;
Radford et al., 1995; Sordat et al., 2002). Silencing CD63 by
RNAi results in increased cell motility and matrix-degrading
ability in melanoma cells (Jang and Lee, 2003), suggesting a
possible involvement of CD63 in the process of melanoma
EMT. Several tetraspanin molecules have been identified and
implicated in the regulation of cell proliferation and migration,
including CD151 tetraspanin described as an important EMT
promoter in hepatocellular carcinoma (Ke et al., 2011).
In this study, using CD63 loss- and gain-of-gene-function
approaches on two human melanoma cell lines and one
primary human melanoma cell line isolated from a cutaneous
metastasis, we demonstrate the CD63 tetraspanin as a potent
inhibitor of EMT program in melanoma, disclosing a pre-
viously unrecognized function of this tetraspanin in melanoma
progression.
RESULTS
CD63 silencing in human melanoma cells and EMT hallmarks
We used two human melanoma established cell lines, A375
and M21, derived from primary tumors, and one primary
human melanoma cell line, SSM2c, isolated from a cutaneous
melanoma metastasis. Western blot analysis revealed high
levels of endogenous CD63 protein in A375 and M21 cells,
displaying a broad range of bands between 30 and 60 kDa
because of its heavy N-glycosylation (Pols and Klumperman,
2009). According to our expectation, low levels of CD63
protein characterized metastatic SSM2c cells (Figure 1a).
Immunofluorescence analyses showed predominant cytoplas-
mic localization of the endogenous CD63 protein in the A375
and M21 cells (Figure 1b), whereas, as expected, we were
unable to detect the CD63 protein in SSM2c cells because of
its low level. Hence, to unravel the role of CD63 in melanoma
cells, we used specific siRNAs to transiently silence the CD63
gene. The CD63 protein expression was reduced more than
80% in both A375 and M21 cells and was undetectable in
SSM2c cells (Figure 1a). Immunofluorescence analyses of
CD63 protein expression on A375 and M21 cells confirmed
effective CD63 silencing (Figure 1b). The impact of a reduced
expression of CD63 on cell motility and invasion of A375 cells
was evaluated. A375 cells with silenced CD63 were able to
repair the wound more rapidly as compared with controls
(Figure 1c) and showed increased invasiveness through
Matrigel-coated filters (Figure 1d), whereas Ilomastast, a
general inhibitor of matrix metalloproteinases (MMPs),
reduced cell invasiveness. Indeed, MMP9 expression and the
MMP9 and MMP2 activity, both enzymes having a key role in
mesenchymal invasion, significantly increased in A375 cells
with silenced CD63 (Figure 1e and f). Silencing of CD63
also resulted in increased invasion of M21 and SSM2c cells
through Matrigel-coated filters (Figure 1d). Moreover, the
evaluation of classical EMT markers in A375 cells with
silenced CD63 showed increased expression of N-cadherin
and Snail and reduction of E-cadherin transcripts (Figure 1f),
whereas quantitative western blot analyses revealed a
decrease in E-cadherin/N-cadherin protein ratio in A375,
M21, and SSM2c cells (Figure 1g). Therefore, CD63 silencing
drives an aggressive phenotype in melanoma cells also
characterized by a cadherin switch.
CD63 overexpression in human melanoma cells and EMT
hallmarks
To gain insight into the functional aspects of CD63, we first
transiently transfected melanoma cells with a human CD63
cDNA, resulting in a strong CD63 overexpression in A375 and
SSM2c cells and mild overexpression in M21 cells (Figure 2a).
A375 cells with CD63 overexpression exhibited a reduced
ability of wound repair (Figure 2b), whereas the A375, M21
and SSM2c cells overexpressing CD63 showed a robust
reduction of invasiveness (Figure 2c) compared with mock-
transfected cells. To strengthen these observations, we pro-
duced stable CD63 clones of A375 cells and we isolated
four of them, G9-61, G9-24, G9-21, and G9-26, expressing
increasing levels of CD63 protein, as determined by quantita-
tive immunoblot analyses (Figure 3a). Next, the results con-
firmed that CD63 stable transfectants exhibited significantly
reduced motility (Figure 3b) and invasiveness (Figure 3c). As
shown in Figure 3d, the last was a consequence of reduced
MMP-9 and MMP-2 activity. Statistical analyses revealed that
motility, invasiveness, and MMP-9 and MMP-2 activity nega-
tively correlated with the CD63 expression level (Figure 3e).
We reasoned whether invasiveness inhibition of CD63-over-
expressing clones was restored by external stimuli—e.g.,
media conditioned by A375 cells silenced for CD63. As
shown in Figure 3f, the enhanced invasiveness stimulated by
Figure 1. Effects of CD63 silencing. (a) Immunoblot analysis (left) of CD63 expression level in A375, M21, and SSM2c cells. Immunoblot analysis (right) of CD63
silencing, including quantitative analysis. GAPDH served as an internal control. *Po0.05 vs. siRNA deg. (b) Representative confocal microscopy images of
CD63 (green fluorescence) in A375 and M21 silenced cells. Nuclear staining (4’,6-diamidino-2-phenylindole (DAPI), blue fluorescence); phalloidin staining of the
actin cytoskeleton (red fluorescence); bar ¼ 25mm. (c) Representative images (top) of the effect of CD63 silencing on A375 cell migration. Images are taken
immediately after scratching the cultures (T0) and 6 hours, 12 hours, or 24 hours later. Quantitative analysis (bottom) of the area not occupied by A375 cells in the
wound healing assay. *Po0.05 vs. siRNA deg. (d) Representative images (top) of the effect of CD63 silencing and Ilomastat treatment on Matrigel invasion by
A375 cells (bar ¼ 100mm). Quantitative analysis (bottom) of the number of A375, M21, and SSM2c cells migrated through Matrigel. *Po0.05 vs. siRNA deg,
**Po0.05 vs. untreated. (e) Representative images (left) of gelatine zymogram for MMP-2 and MMP-9 (HT1080 used as standard) in A375 cells. Quantitative
analysis (right) of MMP-2 and MMP-9 activity. *Po0.05 vs. siRNA deg. (f) Quantitative analysis of MMP2, MMP9, N-Cadherin, Snail, and E-Cadherin mRNAs
on A375 cells by quantitative real-time reverse-transcriptase–PCR. *Po0.05 vs. siRNA deg. (g) Immunoblot analysis (left) of E-cadherin and N-cadherin in
CD63-silenced A375, M21, and SSM2c cells. a-Tubulin served as an internal control. Relative E-cadherin/N-cadherin protein ratio (right). *Po0.05 vs. siRNA deg.
Error bars indicate the means±SD of three independent experiments.
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media conditioned by A375 cells silenced for CD63 was
lower in clones expressing the highest level of CD63,
suggesting a resistance to acquire an invasive phenotype. To
confirm a reduced aggressiveness of G9-26 cells in vivo, A375
mock and G9-26 cells were inoculated into SCID bg/bg
immunodeficient mice. Figure 4 clearly indicates that the
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incidence of G9-26 tumors (number of tumor-bearing
animals/number of injected animals) was reduced and reached
50% of controls on the 19th day of observation and did not
change afterwards, whereas the incidence of control tumors
reached 100% on the 12th day after inoculation. Moreover, the
growth rate of G9-26 tumors was significantly reduced.
The evaluation of classical EMT markers showed reduced
levels of N-cadherin and Snail transcripts, whereas the level of
E-cadherin transcript was increased in G9-26 cells in compar-
ison with mock cells (Figure 5a); thus, increased E-cadherin/N-
cadherin protein ratio was also observed (Figure 5b). To shed
light on the mechanism by which CD63 overexpression
correlates negatively with EMT, and counteracts EMT devel-
opment, we stimulated A375 mock and G9-26 cells with
TGFb. Analysis of cell morphology revealed that untreated
mock and G9-26 cells exhibited cobblestone-like shape
(Figure 5c), whereas treatment with TGFb induced an elon-
gated mesenchymal-like phenotype in mock cells, but not
in G9-26 cells. Moreover, the TGFb-stimulated mock cells
exhibited a significant increase in Snail and N-cadherin
transcripts and a robust decrease in E-cadherin transcript
(Figure 5a), and a decreased E-cadherin/N-cadherin protein
ratio and an increased Zeb1, a-SMA, and Vimentin expres-
sion, altogether suggesting a clear mesenchymal transition
(Figure 5b and d). In contrast, TGFb-stimulated G9-26 cells
exhibited neither a morphology change nor a significant
upregulation of Snail and N-cadherin transcripts (Figure 5a
and c). Furthermore, the reduction of E-cadherin transcript was
threefold less than in controls (Figure 5a), and the E-cadherin/
N-cadherin protein ratio and Zeb1, a-SMA, and Vimentin
expressions confirmed the resistance of G9-26 cells to
undergo transition to a mesenchymal phenotype after TGFb
stimulation (Figure 5b and d). Furthermore, the ability to
acquire high resistance to epithelial–mesenchymal transition
as unveiled by the E-cadherin/N-cadherin protein ratio and
Vimentin and Zeb1 protein expression was found to be a
common feature of the TGFb-stimulated M21 and SSM2c cells
transiently overexpressing CD63, and of G9-26 cells, which
are stable CD63 transfectants (Figure 5e).
On the whole, we might surmise a role of CD63 in
melanoma EMT abrogation.
CD63 expression in human melanoma specimens
To establish a link with human melanoma, we determined
the expression of CD63 protein in specimens from human
melanocytic and dysplastic nevi, primary thin melanoma with
Breslow’s depth o1 mm, primary thick melanoma with
Breslow’s depth 41 mm, and metastatic melanoma. To assess
the relative expression levels of CD63 in the various stages of
melanoma, the immunohistochemical staining of CD63 was
scored in a semiquantitative manner by examination of
the cytoplasmic staining intensity (Figure 6). In normal and
dysplastic nevi, strong staining of CD63 was expressed by
melanocytes (high expression in five out of five samples);
strong staining of CD63 was also observed in primary thin
melanoma (high expression in five out of five samples),
whereas in primary thick melanoma (moderate expression in
three out of five samples, low expression in two out of five
samples) and metastatic tissues (weak/absent expression in five
out of five samples) very low CD63 expression was observed.
These data further suggest the involvement of CD63 in the
inhibition of melanoma progression.
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Figure 2. Effects of CD63 transient overexpression. (a) Immunoblot analysis of
CD63 expression in the transfected A375, M21, and SSM2c cells. GAPDH
served as an internal control. (b) Representative images (top) of the wound
healing assay on A375 cells. Images are taken immediately after scratching (T0)
and 6 hours, 12 hours, or 24 hours later. Quantitative analysis (bottom) of the
area not occupied by A375 cells in the wound healing assay. *Po0.05 vs.
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Error bars indicate the means±SD of three independent experiments.
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G9-61. $Po0.03 vs. G9-61 and G9-24. (c) Representative images (top) of the invasion in Matrigel (bar ¼ 100mm) and quantitative analysis (bottom) of the number
of cells migrated through Matrigel. *Po0.05 vs. mock. #Po0.03 vs. G9-61 and G9-24. (d) Representative images (top) of gelatine zymograms for MMP-2 and
MMP-9. Quantitative analysis (bottom) of MMP-2 and MMP-9 activity (HT1080 used as standard). *Po0.05 vs. mock. (e) Correlation between CD63 expression
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DISCUSSION
In the present study, we used silencing and overexpressing
procedures to demonstrate in vitro and in vivo that CD63
tetraspanin is a potent negative regulator of EMT in melanoma
cells. We used these methodological approaches to recapitulate
biological conditions observed in patients with melanoma; e.g.,
in primary melanoma, Breslow’s depth o1mm, CD63 is
strongly expressed and in primary melanoma, Breslow’s depth
41mm, the tendency is a weak or lack of CD63 expression
(Radford et al., 1995), which was also demonstrated and con-
firmed in this study. Our CD63 silencing data indicated that
reduction in CD63 expression is associated with an increase in
cell motility and MMP-mediated invasiveness. These events
were linked to a reduction in E-cadherin expression. We
also found that CD63 silencing induces the expression of
mesenchymal markers N-cadherin and Snail transcription
factor, sustaining a shift toward a mesenchymal phenotype.
Next, we demonstrated that melanoma cells overexpressing
CD63 in transient show a reduction in cell motility and
invasiveness. These findings were confirmed in stable
transfected clones, in which the level of CD63 expression
coincided with a proportional reduction in MMP-2 and
MMP-9. Interestingly, clone G9-26 with the highest level of
CD63 exhibited a strong resistance to invade when exposed to
pro-invasive stimuli of media conditioned by CD63-silenced
melanoma cells. Evaluation of the tumorigenicity of clone
G9-26 confirmed a significantly reduced incidence and
growth rate of tumors compared with controls.
It is known that tetraspanins regulate cellular invasiveness
through their association with peptidases, ADAMs, MMPs
(Blackburn et al., 2009), and urokinase-type of plasminogen
activator surface receptor (Zoller, 2009). Moreover, over-
expression of CD63 in human embryonic kidney cells deter-
mines a reduction of membrane-associated type-1 matrix
metalloprotease (MT1-MMP) (Takino et al., 2003). In agree-
ment with our in vivo results, overexpression of CD63
suppressed tumorigenicity of H-ras-transformed NIH3T3 cells
in athymic nude mice (Hotta et al., 1991). Transfection of
genomic CD63 into CD63-negative melanoma cells also
inhibited in vivo growth of melanoma cells, and the CD63-
transfected cells gave a reduced number of metastases in the
peritoneal cavity and subcutaneous sites when injected
intravenously (Radford et al., 1995).
The increased expression of E-cadherin, associated with
reduction of Snail in the G9-26 clone, points to a mechanistic
link of CD63, Snail and E-cadherin transcription. Evaluation of
classical EMT markers, particularly the E/N-cadherin ratio,
Vimentin, a-SMA, and Zeb1, demonstrated that the G9-26
clone was resistant to the pro-EMT effect exerted by TGFb
stimulation. TGFb represents the classical stimulus of EMT,
and the TGFb resistance acquired by the G9-26 clone suggests
an essential role of CD63 in the EMT program. Our finding
together with the recent indication that tetraspanin CD151
participates in the promotion of EMT in HCC cells (Ke et al.,
2011) bolsters the importance of tetraspanins in the
mechanism of EMT. Among the different interactions of CD63
with cell surface proteins, integrins are crucial and CD63 inter-
acts with a4b1, a3b1, a6b1, LFA-1, and b2 (Berditchevski et al.,
1996; Skubitz et al., 1996), but the effect of these interactions is
largely unknown. Recently, Hong et al. (2014) reported that
tetraspanin CD81 cooperates with a3b1/a5b1 integrins to
stimulate Akt-dependent Sp1 activation signaling pathways,
leading to an increase in MT1-MMP and motility in
melanoma cells. In colon cancer, the expression of CD63
appears positively correlated with the expression of integrin
a3b1 (Sordat et al., 2002). Therefore, it is possible that CD63
influences the activity and stability of integrins via its interaction
with other tetraspanins in tetraspanin-enriched microdomains.
This study, to our knowledge, discloses a previously
unrecognized role of CD63 in inhibiting the EMT program
in melanoma cells, and our findings contribute to define an
important mechanism of melanoma progression.
MATERIALS AND METHODS
Cell lines, treatments, and antibodies
A375 (provided from ATCC), M21 (obtained as reported (Montgomery
et al., 1996)), and SSM2c (kind gift from Dr Stecca B., Laboratory
of Tumor Cell Biology, Istituto Toscano Tumori (ITT) Italy (Santini
et al., 2012)) human melanoma cells were cultured in DMEM
supplemented with 10% fetal bovine serum, 100 U ml 1 penicillin
G, 100mg ml 1 streptomycin, and 2 mM L-glutamine (Sigma-Aldrich,
St. Louis, MO), in 5% CO2 at 37 1C in a humidified incubator. Stable
clones were maintained in growth medium containing 1 mg ml 1
geneticin (G418, Sigma-Aldrich).
Primary antibodies used in immunoblot analyses are as follows:
mouse monoclonal anti-CD63 (1:100, MA1-26352, Thermo Scien-
tific, Boston, MA); rabbit polyclonal anti-N-cadherin (1:1,000,
GTX112734, GeneTex, Irvine, CA); rabbit polyclonal anti-E-cadherin
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Figure 5. Evaluation of epithelial-to-mesenchymal transition markers in TGFb-treated melanoma cells overexpressing CD63. (a) Quantitative analysis of E-
Cadherin (left), N-Cadherin (middle), and Snail (right) mRNAs in TGFb-treated A375 mock and G9-26 cells by quantitative real-time reverse-transcriptase–PCR.
*Po0.05 vs. untreated mock; #Po0.05 vs. untreated mock; **Po0.05 vs. TGFb-treated G9-26 cells. (b) Immunoblot analysis (left) of E-cadherin, N-cadherin,
Vimentin, and Zeb1 on TGFb-treated A375 mock and G9-26 cells. Relative E-cadherin/N-cadherin protein ratio (right). a-Tubulin served as an internal control.
*Po0.05 vs. untreated mock; **Po0.05 vs. untreated mock. (c) Morphological changes of TGFb-treated A375 mock and G9-26 cells. (d) Representative
confocal microscopy for a-SMA (left, green fluorescence) or Vimentin (right, green fluorescence) in TGFb-treated A375 mock and G9-26 cells. Nuclear staining
(4’,6-diamidino-2-phenylindole (DAPI), blue fluorescence); bar ¼ 25mm. (e) Immunoblot analysis (left) of E-cadherin, N-cadherin, and Vimentin in TGFb-treated
M21 mock and CD63-overexpressing cells. Immunoblot analysis (middle) of E-cadherin, N-cadherin, and Zeb1 in TGFb-treated SSM2c mock and CD63-
overexpressing cells. Relative E-cadherin/N-cadherin protein ratio (right). a-Tubulin served as an internal control. *Po0.05 vs. untreated mock; **Po0.05 vs.
untreated mock. Error bars indicate the means±SD of three independent experiments.
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(1:2,000, GTX100443, GeneTex); rabbit polyclonal anti-Zeb1 (1:100,
sc-25388, Santa Cruz Biotechnology, Dallas, TX); mouse monoclonal
anti-Vimentin (1:200, V6630, Sigma-Aldrich); mouse monoclonal
anti-a-Tubulin (1:3,000, T9060, Sigma-Aldrich); and rabbit mono-
clonal anti-GAPDH (1:1,000, 2118 Cell Signaling, Danvers, MA).
Secondary antibodies used in immunoblot analyses are as
follows: IRDye 800CW goat anti-rabbit (1:12,000, 926-32210, Lycor
Bioscience, Lincoln, NE) and IRDye 800CW goat anti-mouse
(1:12,000, 926-32211, Lycor Bioscience). Primary antibodies used
in immunofluorescence analyses are as follows: rabbit polyclonal
anti-CD63 (1:100, H-193, sc-15363, Santa Cruz Biotechnology);
mouse monoclonal anti-Vimentin (1:200, V6630, Sigma-Aldrich);
and mouse monoclonal anti-aSMA (1:200, A2547, Sigma-Aldrich).
Secondary antibodies used in immunofluorescence analyses are as
follows: Cy-2-conjugated goat anti-rabbit (1:700, AP132J, Chemicon
International, Temecula, CA) and DyLight 488-conjugated goat anti-
mouse (1:700, 072-03-18-06, KPL, Gaithersburg, MD). The primary
antibody used in immunohistochemical analyses was mouse mono-
clonal anti-CD63 (1:500, MA1-26352, Thermo Scientific).
RNA extraction, quantitative real-time PCR, and plasmid
construction
Total RNA isolated with the NucleoSpin II Extraction Kit (Macherey-
Nagel, Duren, Germany) was quantified with a Q-bit spectrophot-
ometer (Qiagen, Venlo, Netherlands) and qualified by 1.5% PAGE. A
volume of 500 ng RNA was then retrotranscribed using ImProm-II
reverse transcriptase (Promega, Madison, WI).
Quantitative real-time PCR (qPCR) was performed using GoTaq
qPCR Master Mix (Promega). The qPCR analysis was carried out in
triplicate using the 7500 Fast Real-Time PCR System (Applied
Biosystems, Carlsbad, CA). The primers were designed according to
published human cDNA sequences in the Genbank database, using
FastPCR software (Kalendar et al., 2011): N-Cadherin 50-CACTGCT
CAGGACCCAGAT-30 forward and 50-TAAGCCGAGTGATGGTCC-30
reverse; E-Cadherin 50-CGGGAATGCAGTTGAGGATC-30 forward
and 50-AGGATGGTGTAAGCGATGGC-30 reverse; SNAIL 50-CCCA
GTGCCTCGACCACTAT-30 forward and 50-CCAGATGAGCATTGGC
AG-30 reverse; 18S 50-CGCCGCTAGAGGTGAAATTCT-30 forward
and 50-CGAACCTCCGACTTTCGTTCT-30 reverse. mRNA was quanti-
fied with the DDCt method. mRNA levels were normalized to 18S as
an endogenous control.
For transfection of recombinant CD63, a 720-bp fragment corre-
sponding to the entire open reading frame of CD63 was PCR-
amplified using 50-CGCGGATCCGCCACCATGGACTACAAGGA
CGACGATGACAGGATGGCGGTGGAAGGAGGAATGAAATGTG-30
(containing FLAG coding sequence) and 50-CCGGAATTCCATCACCT
CGTAGCCACTTCTGATACTC-30 as forward and reverse primer,
respectively. cDNA product was cloned into the pcDNA3.1(þ )
vector (Life Technologies, Carlsbad, CA) using the BamHI and EcoRI
sites to obtain the pCDNA3.1(þ )CD63-FLAG vector.
Transient and stable transfection of recombinant CD63
The melanoma cells were lipotransfected with pCDNA3.1(þ )CD63-
FLAG vector or the empty pcDNA3.1(þ ) vector, as control, with
Lipofectamine LTX (Life Technologies) according to the manufac-
turer’s instructions. Briefly, 1.5 105 cells were seeded in 35 mm
dishes and allowed to reach 80% confluence. Lipofectamine LTX
reagents and DNA were diluted in Opti-Mem medium (Sigma-
Aldrich) and incubated at room temperature for 30 minutes. DNA-
Lipofectamine LTX complexes were then added to the cells in DMEM
serum-free medium and incubated for 24 hours to produce transiently
transfected cells. Western blot analysis with anti-Flag antibody was
performed to verify the efficiency of transient transfection. After
48 hours, transiently transfected A375 cells were split and subcultured
in media containing genetycin (G418, 1 mg ml 1) for selection of
stable clones overexpressing CD63 and stable clones containing the
empty vector used as control (mock). Subsequently, CD63-positive
clones were analyzed by flow cytometry and western blot and chosen
to produce CD63-overexpressing cell lines.
CD63 silencing
Endoribonuclease-prepared siRNAs for CD63 (esiRNAs) and control
siRNAs were purchased from Sigma-Aldrich. esiRNAs are pools of
siRNAs that all target the same mRNA sequence, ensuring high
specificity and minimal risk of off-target effects (Kittler et al., 2007).
Transfection of siRNA was performed using Lipofectamine RNAiMAX
(Life Technologies) according to the manufacturer’s instructions.
Melanoma cells (1.5 105) were seeded in 35 mm dishes and
allowed to reach 50–60% confluence. The final siRNA concentration
used for transfection was 100 nM. The Lipofectamine RNAiMAX
reagent and siRNAs were diluted in Opti-Mem and incubated at
room temperature for 20 minutes. siRNAs–Lipofectamine RNAiMAX
Melanocytic nevus Dysplastic nevus Thin melanoma
Breslow’s depth <1 mm
Thick melanoma
Breslow’s depth >1 mm
Melanoma metastasis
Figure 6. Immunohistochemical staining of CD63. Representative immunohistochemical staining of the CD63 protein (red color) in a melanocytic nevus,
dysplastic nevus, thin melanoma (Breslow’s depth o1 mm), thick melanoma (Breslow’s depth 41 mm), and melanoma metastasis; bar ¼ 50mm.
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complexes were then added to the cells in DMEM serum-free
medium and incubated for 48 hours. Western blot was performed to
verify the efficiency of silencing.
Western blot analysis
Cell pellets obtained by centrifugation were incubated with RIPA lysis
buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium
deoxycholate, 0.1% SDS, 5 mM EDTA) and proteinase inhibitor
cocktail (Roche, Mannheim, Germany) for 30 minutes on ice. Lysates
were then centrifuged at 14,000 r.p.m. for 20 minutes and the super-
natants were collected and stored at  80 1C. Protein content was
quantified by the Bradford method (Bio-Rad, Hercules, CA). Fifty
micrograms of total protein were denaturated at 90 1C for five minutes
and separated on MiniProtran TGX precast gels (Bio-Rad) with 200 V
for 30 minutes under nonreducing conditions. After separation, the
proteins were electroblotted to nitrocellulose membranes with semi-
dry Trans-Blot (Bio-Rad) using constant 0.33 A, 20 V, for 30 minutes.
Transfer efficiency was verified with Ponceau solution and mem-
branes were incubated in a blocking solution consisting of phosphate-
buffered saline (PBS)/Odyssey Blocking Buffer 1:1 (PBS/OBB) (Lycor
Bioscience) for 1 hour at room temperature. Membranes were then
incubated overnight at 4 1C with the appropriate antibody, washed
four times with PBS-Tween 0.1% solution, and probed with the
secondary IRDye antibodies according to the manufacturer’s instruc-
tions. The protein bands were analyzed by the Odyssey Infrared Imag-
ing System (Lycor Bioscience) using software for protein quantification.
Wound healing assay
Cell migration was evaluated by an in vitro wound healing assay.
Cultured cell monolayers at 90% confluence were wounded with a
sterile 200ml pipette tip and then incubated in a growth medium
containing 1% fetal bovine serum for 24hours. Cell migration toward
the wounded area was time-lapse videomicroscopy registered at 0, 6,
12, and 24hours, using a Zeiss (Oberkochen, Germany) inverted phase-
contrast microscope equipped with a  10 objective and CCD cameras.
Matrigel invasion assay
An invasion assay was conducted in a Matrigel Basement Membrane
Matrix (10 mg per mg, BD) on Millicell cell culture Insert (24-well PCF
8.0mm, Millipore, Billerica, MA). The Matrigel diluted at 35mg ml 1
served to coat the membrane of the Millicell upper chamber (100ml in
DMEM serum-free medium) in a 24-well plate overnight. Next day,
Matrigel was rehydrated with 200ml DMEM serum-free medium and
8 104 cells were seeded into the upper chamber in 400ml serum-free
growth medium. The lower chamber contained the complete growth
medium to attract invading cells. Cells transfected with siRNA and
cells overexpressing CD63 were incubated for 24 hours, and the
noninvading cells on the upper surface of Matrigel matrix were
removed by cotton swabs. The cells that invaded across the matrix
to the lower surface of the membrane were fixed and stained with a
Diff Quick Kit and photographs of five random fields per culture were
taken under an inverted microscope equipped with  10 and  20
lenses. The cell count from at least three experiments was expressed as
the average number (±SD) of invading cells from five fields.
Zymography assay
Gelatine zymography was performed to determine the activity of
MMP-2 and MMP-9. A375 cells were starved with serum-free growth
medium for 24 and 48 hours and medium was collected to determine
the protein concentration with Amicon Ultra-0.5 ml centrifugal filter
devices (Millipore). The proteins in the medium were then fractionated
on 10% SDS-PAGE containing 1 mg ml 1 gelatine. HT1080 fibro-
sarcoma cell (ATCC) extract was used as MMP standard. The gel
renaturation was achieved in 2.5% Triton X-100 in deionized water
with gentle agitation for 30 minutes at room temperature, followed by
incubation in developing buffer (50 mM Tris-HCl, 0.2 M NaCl, 5 mM
CaCl2, pH 7.4) overnight with gentle shaking at 37 1C and staining with
a fixing–staining solution (0.5% Comassie Blue in methanol/water/
acetic acid in the ratio 5:5:1) for 2 hours at room temperature. The gel
destained in a solution of methanol/water/acetic acid was then scanned
on a Odyssey Infrared Imaging System and quantified with ImageJ
software (developed by Wayne Rasband, National Institutes of Health,
Bethesda, MD; available at http://rsbweb.nih.gov/ij/index.html).
Xenograft experiments
All experimental procedures involving animals were performed in
accordance with the Italian Guidelines and approved by the ethical
committee of Animal Welfare Office of Italian Work Ministry. Female
SCID bg/bg mice aged 6–8 weeks (Charles River Laboratories
International, Lecco, Italy) were fed with a regular chow diet (Harlan
Laboratories, Indianapolis, IN) and water ad libitum. Human mela-
noma cells were harvested by mild trypsinization, washed twice in
PBS, and then suspended in serum-free medium at 5 106cells per ml;
0.2 ml of cell suspension was injected subcutaneously into the flank of
mice (six animals per group). Animals were monitored daily and tumor
size was measured every 2–3 days by a calliper, and tumor volumes
were determined by the following formula: volume¼ LW2/2, where L
and W are the length and width of the masses. Animals were killed
before tumors exceeded a size to produce evident physical discomfort
such as rough hair coat, lack of grooming activity, or abnormal posture.
Immunofluorescence analysis
Cells were grown on glass coverslips, washed twice with 1 ml of cold
PBS, and fixed for 20 minutes in 3.7% paraformaldehyde in PBS and
permeabilized with 0.1% Triton X-100 in PBS for 5 minutes. After
staining of the nuclei with Hoechst 33242 dye (4’,6-diamidino-2-
phenylindole; Life Technologies) and of the actin cytoskeleton with
TRITC-labeled phalloidin (Sigma-Aldrich) for 30 minutes at room
temperature, the cells were incubated in blocking buffer (3% BSA and
0.1% Triton X-100 in PBS) for 1hour at room temperature. Successively,
the cells were incubated at room temperature for 2hours with the
indicated primary antibodies and for 1hour with the specific secondary
antibody at room temperature. Then, the cells were dried, mounted onto
glass slides, and examined with confocal microscopy using a Nikon
Eclipse TE2000-U (Nikon, Tokyo, Japan). A single composite image was
obtained by superimposition of 20 optical sections for each sample
observed. The collected images were analyzed by ImageJ software
(developed by Wayne Rasband, National Institutes of Health, Bethesda,
MD; available at http://rsbweb.nih.gov/ij/index.html).
Immunohistochemical analysis
Immunohistochemical analysis was performed on selected archival
sections of formalin-fixed, paraffin-embedded human biopsies,
including five melanocytic nevi, five displastic nevi, five thin
melanomas, five thick melanomas, and five melanoma metastases.
The specimens were kindly provided by the Pathological Anatomy
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Unit, Santa Maria Annunziata Hospital, Florence, Italy. The 7-mm
sections were deparaffinized with toluene for 15 minutes, rehydrated
with decreasing concentrations of alcohol, and washed with ddH2O.
The antigens in sections were retrieved by immersion in citrate buffer
(pH 6.0) and warmed in a microwave oven for 15 minutes. After two
washes in PBS, the nonspecific background was eliminated by incuba-
tion in Ultra V Block (Thermo Scientific) for 10minutes at room
temperature, and the sections were incubated with the indicated primary
antibody for 2hours at 37 1C. Immunostaining was carried out using the
Lab Vision UltraVision LP Detection System–AP Polymer/Fast Red
Chromogen (Thermo Scientific), according to the manufacturer’s instruc-
tions. The nuclei were counterstained with hematoxylin for 5minutes,
and subsequently mounted on glass slides using a Canada balsam for
light microscopy examination. To assess the relative expression levels of
CD63 in the various stages of melanoma, the immunohistochemical
staining of CD63 was scored in a semiquantitative manner by examina-
tion of the cytoplasmic staining intensity by an experienced pathologist.
Statistical analysis
Data are presented as means±SD of at least three independent
experiments. The unpaired Student t-test was performed to evaluate
pair-wise differences, with Po0.05 being considered significant. The
Spearman rank correlation coefficient was used to calculate the
correlation between CD63 expression level and migration, invasion,
and MMP activity of melanoma cells.
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